Wolchok, J. Placing the immunologic brakes on most cancers. Cell 175, 1452–1454 (2018).
Bonaventura, P. et al. Chilly tumors: a therapeutic problem for immunotherapy. Entrance. Immunol. 10, 168–168 (2019).
Galon, J. & Bruni, D. Approaches to deal with immune sizzling, altered and chilly tumours with mixture immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
Haanen, J. B. A. G. Changing chilly into sizzling tumors by combining immunotherapies. Cell 170, 1055–1056 (2017).
Kulkarni, A. et al. Reporter nanoparticle that displays its anticancer efficacy in actual time. Proc. Natl Acad. Sci. USA 113, E2104–E2113 (2016).
Gabizon, A. et al. Extended circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Most cancers Res. 54, 987–992 (1994).
Sengupta, S. et al. Lipid-based platinum compounds and nanoparticles. US patent 10,730,899 B2 (2020).
Paraskar, A., Soni, S., Roy, B., Papa, A. L. & Sengupta, S. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 23, 075103 (2012).
Paraskar, A. S. et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc. Natl Acad. Sci. USA 107, 12435–12440 (2010).
Sengupta, P. et al. Ldl cholesterol-tethered platinum II-based supramolecular nanoparticle will increase antitumor efficacy and reduces nephrotoxicity. Proc. Natl Acad. Sci. USA 109, 11294–11299 (2012).
Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in excessive mutation burden mouse fashions of breast most cancers. Cell 179, 1191–1206.e1121 (2019).
Helmink, B. A. et al. B cells and tertiary lymphoid buildings promote immunotherapy response. Nature 577, 549–555 (2020).
Petitprez, F. et al. B cells are related to survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
Candolfi, M. et al. B cells are crucial to T-cell-mediated antitumor immunity induced by a mixed immune-stimulatory/ conditionally cytotoxic remedy for glioblastoma. Neoplasia 13, 947–960 (2011).
Griss, J. et al. B cells maintain irritation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V. & Chudakov, D. M. B cells, plasma cells and antibody repertoires within the tumour microenvironment. Nat. Rev. Immunol. 20, 294–307 (2020).
Bod, L. et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature https://doi.org/10.1038/s41586-023-06231-0 (2023).
Wieland, A. et al. Defining HPV-specific B cell responses in sufferers with head and neck most cancers. Nature https://doi.org/10.1038/s41586-020-2931-3 (2020).
Despic, V. & Jaffrey, S. R. mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature 614, 358–366 (2023).
Takahara, P. M., Rosenzweig, A. C., Frederick, C. A. & Lippard, S. J. Crystal construction of double-stranded DNA containing the key adduct of the anticancer drug cisplatin. Nature 377, 649–652 (1995).
Kulkarni, A. et al. Algorithm for designing nanoscale supramolecular therapeutics with elevated anticancer efficacy. ACS Nano 10, 8154–8168 (2016).
Kulkarni, A. et al. A designer self-assembled supramolecule amplifies macrophage immune responses towards aggressive most cancers. Nat. Biomed. Eng. 2, 589–599 (2018).
Kim, Ok. et al. Eradication of metastatic mouse cancers immune to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774–11779 (2014).
Rupp, T. et al. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor development in preclinical breast and colon mannequin with impartial regulatory T cells response. Transl. Oncol. 20, 101405 (2022).
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell dying in most cancers remedy. Annu. Rev. Immunol. 31, 51–72 (2013).
Denkert, C. et al. Tumor-associated lymphocytes as an impartial predictor of response to neoadjuvant chemotherapy in breast most cancers. J. Clin. Oncol. 28, 105–113 (2009).
Schmidt, M. et al. A complete evaluation of human gene expression profiles identifies stromal immunoglobulin κ C as a appropriate prognostic marker in human stable tumors. Clin. Most cancers Res. 18, 2695–2703 (2012).
Sarvaria, A., Madrigal, J.A. & Saudem ont, A. B cell regulation in most cancers and anti-tumor immunity. Cell Mol. Immunol. 14, 662–674 (2017).
Bhattacharya, D. et al. Transcriptional profiling of antigen-dependent murine B cell differentiation and reminiscence formation. J. Immunol. 179, 6808–6819 (2007).
Hu, Q. et al. Atlas of breast most cancers infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat. Commun. 12, 2186 (2021).
Clutterbuck, E. A. et al. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 119, 328–337 (2006).
Li, Q., Teitz-Tennenbaum, S., Donald, E. J., Li, M. & Chang, A. E. In vivo sensitized and in vitro activated B cells mediate tumor regression in most cancers adoptive immunotherapy. J. Immunol. 183, 3195–3203 (2009).
Chen, J. et al. Immunoglobulin gene rearrangement in B cell poor mice generated by focused deletion of the JH locus. Int. Immunol. 5, 647–656 (1993).
Mylavarapu, S., Das, A. & Roy, M. Position of BRCA mutations within the modulation of response to platinum remedy. Entrance. Oncol. 8, 16 (2018).
Tesniere, A. et al. Immunogenic dying of colon most cancers cells handled with oxaliplatin. Oncogene 29, 482–491 (2010).
Taunton, J., Hassig, C. A. & Schreiber, S. L. A mammalian histone deacetylase associated to the yeast transcriptional regulator Rpd3p. Science 272, 408–411 (1996).
Free, R. B., Hazelwood, L. A. & Sibley, D. R. Figuring out novel protein-protein interactions utilizing co-immunoprecipitation and mass spectroscopy. Curr. Protoc. Neurosci. https://doi.org/10.1002/0471142301.ns0528s46 (2009).
Daffis, S. et al. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT relations. Nature 468, 452–456 (2010).
Abbas, Y. M. et al. Construction of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2′-O methylations. Proc. Natl Acad. Sci. USA 114, E2106–E2115 (2017).
Corso, G. et al. Deep assured steps to new pockets: methods for docking generalization. Preprint at https://doi.org/10.48550/arXiv.2402.18396 (2024).
Smietanski, M. et al. Structural evaluation of human 2′-O-ribose methyltransferases concerned in mRNA cap construction formation. Nat. Commun. 5, 3004 (2014).
Ning, S., Pagano, J. S. & Barber, G. N. IRF7: activation, regulation, modification and performance. Genes Immun. 12, 399–414 (2011).
Diamond, M. S. IFIT1: a twin sensor and effector molecule that detects non-2′-O methylated viral RNA and inhibits its translation. Cytokine Development Issue Rev. 25, 543–550 (2014).
Diamond, M.S. & Farzan, M. The broad-spectrum antiviral features of IFIT and IFITM proteins. Nat. Rev. Immunol. 1, 46–57 (2013).
Geng, J. et al. Cap-related modifications of RNA regulate binding to IFIT proteins. RNA 30, 1292–1305 (2024).
Fensterl, V. & Sen, G. C. Interferon-induced Ifit proteins: their function in viral pathogenesis. J. Virol. 89, 2462 (2015).
Mendoza, E. J., Manguiat, Ok., Wooden, H. & Drebot, M. Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2. Curr. Protoc. Microbiol. 57, ecpmc105 (2020).
Tang, G., Cho, M. & Wang, X. OncoDB: an interactive on-line database for evaluation of gene expression and viral an infection in most cancers. Nucleic Acids Res. 50, D1334–D1339 (2022).
Zeng, Z. et al. TISMO: syngeneic mouse tumor database to mannequin tumor immunity and immunotherapy response. Nucleic Acids Res. 50, D1391–D1397 (2022).
Pimentel, V. O. et al. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when mixed with radiotherapy. J. Immunother. Most cancers 9, e001764 (2021).
Miller, H. E. & Bishop, A. J. R. Correlation AnalyzeR: useful predictions from gene co-expression correlations. BMC Bioinform. 22, 206 (2021).
Hope, J. L. & Bradley, L. M. Classes in antiviral immunity. Science 371, 464–465 (2021).
Reyneveld, G. I., Savelkoul, H. F. J. & Parmentier, H. Ok. Present understanding of pure antibodies and exploring the probabilities of modulation utilizing veterinary fashions. A evaluate. Entrance. Immunol. https://doi.org/10.3389/fimmu.2020.02139 (2020).
Panda, S. & Ding, J. L. Pure antibodies bridge innate and adaptive immunity. J. Immunol. 194, 13–20 (2015).
Zabel, F., Kündig, T. M. & Bachmann, M. F. Virus-induced humoral immunity: on how B cell responses are initiated. Curr. Opin. Virol. 3, 357–362 (2013).
Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208–1222.e1221 (2022).
Upasani, V., Rodenhuis-Zybert, I. & Cantaert, T. Antibody-independent features of B cells throughout viral infections. PLoS Pathog. 17, e1009708 (2021).
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P. & Nelson, B. H. Tumour-infiltrating B cells: immunological mechanisms, medical impression and therapeutic alternatives. Nat. Rev. Most cancers https://doi.org/10.1038/s41568-022-00466-1 (2022).
Cabrita, R. et al. Tertiary lymphoid buildings enhance immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
Kimura, T. et al. Ifit1 inhibits Japanese encephalitis virus replication via binding to five′ capped 2′-O unmethylated RNA. J. Virol. 87, 9997–10003 (2013).
Pichlmair, A. et al. IFIT1 is an antiviral protein that acknowledges 5′-triphosphate RNA. Nat. Immunol. 12, 624–630 (2011).
Kumar, P. et al. Inhibition of translation by IFIT relations is decided by their capability to work together selectively with the 5′-terminal areas of cap0-, cap1- and 5′ppp- mRNAs. Nucleic Acids Res. 42, 3228–3245 (2014).
Hyde, J. L. & Diamond, M. S. Innate immune restriction and antagonism of viral RNA missing 2′-O methylation. Virology 479–480, 66–74 (2015).
Banville, A. C. & Nelson, B. H. Breaching B cell tolerance within the tumor microenvironment. Most cancers Cell 40, 356–358 (2022).
Lam, J. H. & Baumgarth, N. The multifaceted B cell response to influenza virus. J. Immunol. 202, 351–359 (2019).
Quin, J. et al. ADAR RNA modifications, the epitranscriptome and innate immunity. Developments Biochem. Sci. 46, 758–771 (2021).
Bhate, A., Solar, T. & Li, J. B. ADAR1: a brand new goal for immuno-oncology remedy. Mol. Cell 73, 866–868 (2019).
Moreno, V. et al. Remedy with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and together with pembrolizumab in sufferers with superior stable tumors: outcomes from two section 1 research. Most cancers Immunol. Immunother. 71, 2985–2998 (2022).
Brunner, S. M. et al. Tumor-infiltrating B cells producing antitumor energetic immunoglobulins in resected HCC extend affected person survival. Oncotarget 8, 71002–71011 (2017).
Delano, W. L. The PyMOL Molecular Graphics System (DeLano Scientific, 2002).
